BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naive and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain.

Trial Profile

BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naive and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Dabrafenib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Break-MB
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Sep 2013 Dabrafenib was approved by the EC as oral monotherapy for unresectable/metastatic melanoma in patients with BRAF V600 mutation, based on data from BREAK-MB and BREAK-2 and -3, according to a GlaxoSmithKline media release.
    • 08 Jun 2012 Actual patients number is 172 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top